Related Experiment Videos
Griseofulvin inhibition of polymorphonuclear leucocyte chemotaxis in Boyden chambers
Abstract:
Griseofulvin inhibited the chemotaxis of polymorphonuclear leucocytes (PMN's) in vitro in the concentration range 0.1-1.0 mug/ml, i.e. at concentrations comparable to those obtained in serum during peroral treatment with griseofulvin. It is suggested that PMN chemotaxis is inhibited by griseofulvin interference with the redistribution of cytoplasmic microtubules, which is thought to be essential in the direction-finding of PMNs during chemotaxis. Furthermore, it is suggested that the griseofulvin inhibition of PMN chemotaxis - together with the previously known pharmacodynamic properties of griseofulvin - may provide the rationale for griseofulvin therapy in PMN-mediated tissue injury of the gut.
Insights
Griseofulvin inhibits polymorphonuclear leucocyte (PMN) chemotaxis in vitro. This effect, potentially via microtubule interference, may explain its therapeutic use in gut inflammation.
Area of Science:
- Pharmacology
- Immunology
- Cell Biology
Background:
- Griseofulvin is an antifungal medication.
- Polymorphonuclear leucocytes (PMNs) play a role in inflammatory processes.
- Chemotaxis is crucial for PMN function in directing cell movement.
Purpose of the Study:
- To investigate the in vitro effect of griseofulvin on PMN chemotaxis.
- To explore the potential mechanism of griseofulvin's action on PMNs.
- To provide a rationale for griseofulvin's therapeutic application in gut injuries.
Main Methods:
- In vitro assessment of PMN chemotaxis.
- Testing griseofulvin at concentrations (0.1-1.0 mug/ml) relevant to serum levels.
- Hypothesizing griseofulvin's interference with cytoplasmic microtubule redistribution.
Main Results:
- Griseofulvin demonstrated significant inhibition of PMN chemotaxis in vitro.
- The observed inhibitory concentrations are comparable to therapeutic serum levels.
- A proposed mechanism involves griseofulvin disrupting microtubule dynamics essential for PMN directionality.
Conclusions:
- Griseofulvin's inhibition of PMN chemotaxis is a key pharmacodynamic property.
- This inhibition, linked to microtubule interference, supports its use in treating PMN-mediated gut injuries.
- The findings offer a mechanistic insight into griseofulvin's therapeutic efficacy.